Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.
Kevin E. Noonan
Advertisement
Kevin E. Noonan, PhD, noonan@mbhb.com, is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s Biotechnology & Pharmaceuticals Practice Group.
Articles by Kevin E. Noonan
Advertisement
Latest Updated Articles
- Protecting Intellectual Property for COVID-19 Innovations
Published: November 6th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Everything to Know About Pharmaceutical Tariffs in 2025
2
Building Resilience in Pharma: Our Top 10 Questions from CPHI Frankfurt
3
Challenges for the Global Manufacturing of Vaccines
4
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
5
